Table 2.

Studies that evaluated paclitaxel in patients with advanced pancreatic cancer

Clinical trial (year; reference)DesignPatients, NLine(s) of therapy; patient populationRegimenOverall response rateMedian survival (mo)
Cre-paclitaxel
 Gebbia (1996; ref. 16)Phase II14First-line; stage III/IVPaclitaxel 175 mg/m2 every 3 wks0%7.2
 Whitehead (1997; ref. 17)Phase II39First-line; stage III/IVPaclitaxel 250 mg/m2 every 3 wks + G-CSF8%5
 Kim (2008; ref. 21)Phase II28Gemcitabine-refractory; stage III/IVPaclitaxel 175 mg/m2 on day 1 every 4 wks + 5-fluorouracil 1,000 mg/m2 i.v. on days 1–3 every 4 wks10%2.5
 Lam (2009; ref. 18)Phase II19First-line and beyond; stage III/IVPaclitaxel 90 mg/m2 weekly × 3 every 4 wks + bryostatin0%1.9
 Oettle (2000; ref. 20)Retrospective study18Second and third lines; stage IVPaclitaxel 55–88 mg/m2 weekly5%4.3
 Shukuya (2010; ref. 60)Retrospective study23Gemcitabine-refractory; stage III/IVPaclitaxel 80 mg/m2 weekly × 3 every 4 wks0%3.4
 Maeda (2012; ref. 19)Retrospective study30Gemcitabine-refractory; stage III/IVPaclitaxel 80 mg/m2 weekly × 3 every 4 wks10%6.7
nab-paclitaxel
 von Hoff (2011; ref. 9)Phase I/II67First-line; stage IVnab-paclitaxel 100, 125, 150 mg/m2 + gemcitabine 1,000 mg/m2 weekly × 3 every 4 wks46%12.2
 Ko (2012; ref. 24)Phase I15First-line; stage IVnab-paclitaxel 100 mg/m2 (Day 4) + gemcitabine 750 mg/m2 (day 4) + capecitabine 750 mg/m2 twice daily (day 1–7) every 14 days14%7.5
 MPACT (2013; ref. 8)Phase III842First-line; stage IVnab-paclitaxel 125 mg/m2 + gemcitabine 1,000 mg/m2 weekly × 3 every 4 wks23%8.5
 Hosein (2012; ref. 25)Phase II19Second and third lines; stage III/IVnab-paclitaxel 100 mg/m2 weekly × 3 every 4 wks5%7.3
ET-paclitaxel
 Lohr (2012; ref. 27)Phase II randomized200First-line; stage III/IVET-paclitaxel 11, 22, 44 mg/m2 twice-weekly + gemcitabine 1,000 mg/m2 vs. gemcitabine14%/14%/16%/14%, respectively4.1/4.6/4.4/2.7, respectively
GPM-paclitaxel
 Saif (2010; ref. 29)Phase II2010First-line; stage III/IVGPM-paclitaxel 435/300/350 mg/m2 every 3 wks7%6.5